Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

California Prop 65 Complaints Against OTC Generics? Ranitidine Could Be First And Last Target

Mar 21 2023

• By Malcolm Spicer

• Source: Shutterstock

Related Content

Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules

Dec 15 2022

FDA Preemption Comment Could Sway California Against Prop 65 Warnings For Acetaminophen

Jan 29 2020

Sanofi Returning Zantac OTC Heartburn Remedy Brand To US Market Formulated With Famotidine

Apr 28 2021

Federal Preemption Strikes California Prop 65 Complaint Against Generic OTC Ranitidine Firms

Mar 21 2023

Related Companies

Sanofi

Dr. Reddy's Laboratories Ltd.

Perrigo Company PLC

Additional Topics

International United States US States OTC Drugs Legal Issues US State News Business Strategies Commercial Companies Compliance Consumer Distribution Drug Safety FDA Ingredients Manufacturing Packaging Policy Politics Recalls Regulation Retail Safety Supply Chain

More from Legal

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window